{
  "paper_id": "PMC8239833",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239833/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig 2.",
      "caption": "Top: dual expression of TNF alpha (TNF‐α) and interleukin 2 (IL‐2) in CD4+ T cells in dasatinib treated patient. Left, pre‐vaccine; and right, post vaccine. Middle: dual expression of TNF‐α and interferon gamma (IFN‐γ) in CD4+ T cells in imatinib treated patient. Left, unstimulated cells; and right, cells exposed to S protein. Bottom: dual expression of IFN‐γ and IL‐2 in CD4+ T cells in nilotinib treated patient. Left, unstimulated cells; and right, cells exposed to S protein.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/6d67708157ee/BJH-194-999-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/6d67708157ee/BJH-194-999-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/6d67708157ee/BJH-194-999-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/6d67708157ee/BJH-194-999-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "bjh17568-fig-0002",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/6d67708157ee/BJH-194-999-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8239833/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/6d67708157ee/BJH-194-999-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig 3.",
      "caption": "(A) Mean increase in CD4+ T cell TNF alpha (TNF‐α) expression in nilotinib‐treated patients compared with other tyrosine kinase inhibitors (TKIs). (B) Mean increase in CD4+ T cell dual TNF‐α and interferon gamma (IFN‐γ) expression in nilotinib‐treated patients compared with other TKIs.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/51e27dc7beb6/BJH-194-999-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/51e27dc7beb6/BJH-194-999-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/51e27dc7beb6/BJH-194-999-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/51e27dc7beb6/BJH-194-999-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "bjh17568-fig-0003",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/51e27dc7beb6/BJH-194-999-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8239833/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/217f/8239833/51e27dc7beb6/BJH-194-999-g002.jpg"
    }
  },
  "claims": [
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A positive anti‐S IgG ELISA response was seen in 87·5% (14/16) of patients analysed after a first injection, with only two patients showing undetectable IgG to Spike at 1:25 dilution (Table I and Fig 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "3\nAmongst different TKIs the median ID50 was 467 5 for imatinib, 473 for nilotinib, 375·5 for dasatinib, 777 for bosutinib and 102·5 for ponatinib, with no statistical difference seen between TKIs (Fig 1B, P = 0·68).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "A memory T‐cell response was seen in 14 out of 15 evaluable patients (93·3%), with the only patient not showing a T‐cell response being post allogeneic haematopoietic stem cell transplantation (HSCT) and taking ponatinib (Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A SARS‐CoV‐2 specific CD4+ T‐cell response was seen in 80% (12/15) and a SARS‐CoV‐2 specific CD8+ T‐cell response was seen in 60% (nine of 15, Table I and Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A polyfunctional cytokine response in either CD4 or CD8+ T cells was seen in 80% (12/15) of patients, with a polyfunctional CD4+ response in 60% (nine of 15) and a polyfunctional CD8+ T‐cell response in 40% (six of 15) (Fig 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Interestingly patients taking nilotinib had a significantly higher mean increase in TNF‐α expression in CD4+ cells, when compared with patients taking other TKIs (0·83 vs. 0·096, P = 0·015; Fig 3A), and also of dual TNF‐α+/IFN‐γ+ (0·098 vs. 0·009, P = 0·028; Fig 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 2,
    "claims_count": 66,
    "images_downloaded": 2,
    "tables_filtered": 68
  }
}